CN104971190A - Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes - Google Patents
Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes Download PDFInfo
- Publication number
- CN104971190A CN104971190A CN201410135470.9A CN201410135470A CN104971190A CN 104971190 A CN104971190 A CN 104971190A CN 201410135470 A CN201410135470 A CN 201410135470A CN 104971190 A CN104971190 A CN 104971190A
- Authority
- CN
- China
- Prior art keywords
- rhizoma dioscoreae
- medicine
- dioscoreae cirrhosae
- diabetes
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of the diabetes. According to the application disclosed by the invention, dioscorea cirrhosa is deeply developed by modern medicine efficacy research technologies, capable of being processed to prepare proper medicine preparations for preventing or treating diabetes and the complications thereof as a raw material, as well as is obvious in pharmacological activity, stable in performance, and safe and reliable. In addition, the raw materials of dioscorea cirrhosa are easily available in source, the preparation process is easy to industrialize, and the adequate development and utilization of medicinal material resources can be driven.
Description
Technical field
The medical material that the present invention relates to a kind of prevention or treatment diabetes and complication thereof, preparing the application in medicine, belongs to the field of Chinese medicines.
Background technology
Medical material: Rhizoma Dioscoreae Cirrhosae (Dioscorea cirrhosa Lour.)
Ji Yuan: Dioscoreaceae (Dioscoreaceae) Wild yam (Dioscorea)
Former plant: perennial root is wound around liana, Herb Glabrous, and cane is cylindrical, and its matter is very tough and tensile, base portion is long has hard Spina jujubae, top multi-branched, spreads very long, often seeks connections with in arbor or bushes.Leaf alternate or to life, keratin, oblong is to long lanceolar, and the new shape of base portion or obtuse, Quan Lv, front is green, and back side powder is green, all smooth, long 4 ~ 10 centimeters of leaf, wide 2 ~ 5 centimeters.Flower unisexuality, number multiform is little, and staminate inflorescence is coniform, female inflorescence spike, and axil is raw, and capsule three aliform, about 2.5 ~ 3 centimeters, footpath, seed is flat and ensconce in wing, and spring and summer is bloomed, autumn in summer result.Medicinal part tuber is loose, and elder is several sections of, pogoniasis root, rough surface and often have verruca, and its meat is reddish brown or purplish red.
Diabetes be a kind of due to defect of insulin secretion and (or) its biological action obstacle causes take hyperglycemia as the metabolic disease of feature, diabetes have become the chronic disease of the 3rd serious harm human health after tumor, cardiovascular and cerebrovascular disease in the world.Medically generally diabetes type is divided into four kinds: one patients with type Ⅰ DM, type-II diabetes, gestational diabetes and other patients with type Ⅰ DM, type-II diabetes becomes the focus of people's research gradually in recent years.
The medicine being used for the treatment of diabetes at present clinically mainly contains biguanides, thiazolidinediones etc., as the metformin of biguanides, Main Function is the sensitivity improving insulin, increase the utilization of glucose, suppress the output of hepatic glucose, increase quantity and the affinity of Insulin receptor INSR, reduce intestinal to the absorption of glucose, reach therapeutical effect; Rosiglitazone and pioglitazone as euglycemic agent, by improving the sensitivity of insulin at skeletal muscle, fatty tissue, liver and reduce blood glucose.But all have some limitations and untoward reaction, as body weight increase, heart failure, lactic acidosis, life-time service can lead to complications, as Avandia, show the risk more easily increasing the burst of patient's heart disease and heart failure.The current U.S. has limited the use of this quasi drugs, and these medicines will exit European market simultaneously.Therefore, find the little antidiabetic medicine of new side effect and become domestic and international study hotspot.
Summary of the invention
The object of the invention is to, a kind of Rhizoma Dioscoreae Cirrhosae is provided to prevent in preparation or treat the application in the medicine of diabetes and complication thereof, the present invention confirms through experimentation: the pharmacologically active of Rhizoma Dioscoreae Cirrhosae to diabetes and complication thereof is obvious, safe and reliable, can be used for the product preparing prevention or treatment diabetes and complication thereof.
For solving the problems of the technologies described above, the present invention adopts following technical scheme: Rhizoma Dioscoreae Cirrhosae prevents in preparation or treats the application in the medicine of diabetes and complication thereof.
Aforesaid diabetes are type 2 diabetes mellitus; Described complication be vision change, auditory dysesthesia, gingival hemorrhage, xerostomia or ulcer, dizziness or feel dizzy, extremity twinge or numbness, the frequent pain of trick, leg cramps or numbness, intestinal and bladder dysfunction, perspiration are abnormal, xerosis cutis or pruritus, sexual life difficulty, dyslipidemia.
In the present invention, Rhizoma Dioscoreae Cirrhosae is used for prevention or treatment type 2 diabetes mellitus, is take Rhizoma Dioscoreae Cirrhosae as raw material, is prepared into the medicine or health product that are applicable to use clinically.
Aforesaid medicine or health product are powder, tablet, granule, capsule, microcapsule, pill, drop pill, soft capsule, oral liquid, syrup, dispersible tablet, spray or aerosol, intravenous injection, intramuscular dose, inhalant, patch, gel; Adjuvant used is selected from conventional solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent, lubricant, wetting agent, thickening agent, solubilizing agent.
In the present invention, Rhizoma Dioscoreae Cirrhosae is used for prevention or treatment type 2 diabetes mellitus, is the dye yam extract extracted for solvent with water, ethanol or carbon dioxide, is prepared into the medicine or health product that are applicable to use clinically.
Preferably, be that solvent extraction dye yam extract comprises the following steps with water: Rhizoma Dioscoreae Cirrhosae is cut into 0.02 ~ 2cm section, take 80 ~ 120g, with 6 ~ 10 times of water gagings, medical material is infiltrated 30 ~ 120min, decoct 1 ~ 3 time, each 1 ~ 3 hour, filter, merging filtrate, concentrated, in temperature be 65 ~ 75 DEG C, vacuum be the condition of 0.08 ~ 0.1Mpa under drying under reduced pressure, to obtain final product.
Preferred, be that solvent extraction dye yam extract comprises the following steps with water: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, with 8 times of water gagings, medical material is infiltrated 30min, decoct 2 times, each 2 hours, filter, merging filtrate, concentrated, in temperature be 70 DEG C, vacuum be the condition of 0.1Mpa under drying under reduced pressure, to obtain final product.
In the application of aforesaid Rhizoma Dioscoreae Cirrhosae, dye yam extract and other drug regimen for the treatment of diabetes are made compound medicine.
Concrete, by the heat and toxic materials clearing away medicine of dye yam extract with treatment diabetes deficiency of both QI and YIN, circulation promoting vein relaxing medicine, astringent hemostatic, Qi-tonifying drug, the one or more combination in clearing away heat-fire, relieving stuffiness of the chest by dispersing aggregation of pathogens, promoting the production of body fluid to quench thirst medicine makes compound medicine.
Preferably, described heat and toxic materials clearing away medicine is Flos Lonicerae, and circulation promoting vein relaxing medicine is freshly-slaughtered poultry Caulis seu Radix Schisandrae Henryi, and astringent hemostatic is Herba Agrimoniae, Qi-tonifying drug be fresh vertical basin squeeze the juice mix slag zymolysis become song, clearing away heat-fire, relieving stuffiness of the chest by dispersing aggregation of pathogens, promoting the production of body fluid to quench thirst medicine are fresh Fructus Trichosanthis.
In order to ensure effect of the present invention, inventors performed a series of experiment to select the extraction process of dye yam extract provided by the invention, ensure science, reasonable, feasible; Simultaneously in order to verify the action effect of Rhizoma Dioscoreae Cirrhosae in prevention or treatment diabetes and complication thereof, applicant carried out series of experimental research, specific as follows:
Experimental example 1: extract the selection of solvent and roughly selecting of extracting method
Get the coarse powder 100 grams of Rhizoma Dioscoreae Cirrhosae, the scheme according to the form below 1 is tested, and result of the test is as shown in table 2:
The different extraction scheme of table 1
Table 2 different solvents is on the impact of paste-forming rate
As shown in Table 2: Rhizoma Dioscoreae Cirrhosae is with water and carbon dioxide for solvent extracts, and the paste-forming rate of extract is the highest, from cost-saving consideration, select water as optimum extraction solvent, extracting mode is selected to decoct and is extracted.
Experimental example 2:: Rhizoma Dioscoreae Cirrhosae extraction process by water is investigated
One, the process of preparing Chinese medicine length of medical material is on the impact of paste-forming rate
Take Rhizoma Dioscoreae Cirrhosae 100g, with 10 times of water gagings, medical material is infiltrated 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, concentrated, carry out paste-forming rate mensuration, the results are shown in Table 3:
Table 3 medicinal material processing length is on the impact of paste-forming rate
From upper table 3: the paste-forming rate of medicinal material coarse powder is the highest, due to medicinal material coarse powder extract after medicinal liquid be difficult to filter, although the method for available mechanical drains medicinal residues during experiment, but and be not suitable for large commercial production; And the paste-forming rate cutting into the paste-forming rate of medical material of 1.0cm section and medicinal material coarse powder is close, therefore carry out being extracted as good to cut into 1.0cm section.
Two, soak time is on the impact of paste-forming rate
Medical material water absorption rate measures: Rhizoma Dioscoreae Cirrhosae is concocted into 1.0cm section, take 100g, adds water to and soaks medical material completely, spend the night, measure its water absorption rate, the results are shown in Table 4:
Table 4 soaked overnight medical material water absorption rate measures
Take the Rhizoma Dioscoreae Cirrhosae that 100g concocts into 1.0cm section, with 10 times of water gagings, medical material is infiltrated different time, decoct 2 times, each 2 hours, filter, merging filtrate, concentrated, measure paste-forming rate, the results are shown in Table 5:
Table 5
From upper table 5: different soak times, little on the paste-forming rate impact of medical material, from the consideration that saves time and cost, to infiltrate 30 minutes for good.
Three, different amount of water, decocting time and extraction time are on the impact of paste-forming rate
After medicinal material processing length and soak time are determined, according to preliminary experiment, selected on the principal element affecting paste-forming rate: decocting time, extraction time and amount of water, adopt the method for orthogonal experiment, carry out investigating the impact of each link on paste-forming rate with three of Three factors varying levels, thus choose optimised process.Wherein factor level is as shown in table 6:
Table 6 overall merit experimental level
Adopt L
9(3
4) orthogonal table tests, take the Rhizoma Dioscoreae Cirrhosae that 100g concocts into 1.0cm section, undertaken by the factor in table 6 and level conditions, medical material soak time is 30 minutes, after extraction, and extracting solution filters, and filtrate concentrates, and carry out paste-forming rate mensuration, result is as shown in table 7:
Table 7 orthogonal table experimental result
As shown in Table 7: the order of each factor impact is A > B > C, and optimum extraction process is A
2b
2c
2, that is: the Rhizoma Dioscoreae Cirrhosae of concocting into 1.0cm section extracts 2 times, and first time adds 8 times amount water soaking 30 minutes, decocts 2 hours, and second time adds 8 times amount soak by water 2 hours.
Experimental example 3: extraction scheme is verified
According to the experimental condition optimized, take the Rhizoma Dioscoreae Cirrhosae that 10000g concocts into 1.0cm section, extract 2 times, first time adds 8 times amount water soaking 30 minutes, decoct 2 hours, second time adds 8 times amount soak by water 2 hours, after extraction, extracting solution filters, filtrate concentrates, and carries out paste-forming rate mensuration, and remaining concentrate carries out drying under reduced pressure, and (temperature is 65 ~ 75 DEG C, vacuum is 0.08 ~ 0.1Mpa), result is as shown in table 8:
Table 8 extraction scheme is verified
From upper table 8, it is reasonable, feasible that the experimental condition optimized is used for extracting Rhizoma Dioscoreae Cirrhosae.
The concrete grammar that paste-forming rate described in above-mentioned experimental example measures is: get the clear paste being concentrated into relative density 1.20 ~ 1.30 (mensuration temperature 60 C), to be transferred in the volumetric flask of 1000ml and standardize solution, shake up, precision measures the evaporating dish that 20ml is placed in constant weight respectively, and water-bath volatilizes, and residue was in 105 DEG C of dryings 3 hours, take out, put in exsiccator and place 30 minutes, weigh, calculate; The extract water-bath of supercritical carbon dioxide extraction volatilizes, and is dried to constant weight, weighs at being placed in 105 DEG C, calculates.
Experimental example 4 dye yam extract of the present invention is on the impact of type 2 diabetes mellitus rat
1. materials and methods
1.1 material
1.1.1 animal cleaning grade male SD rat, body weight 150 ~ 180g, is purchased from Chongqing and rises prosperous Bill's laboratory animal sale company limited, animal credit number SCXK (Chongqing), 2012-0006.
1.1.2 extract and reagent
1.1.2.1 dye yam extract: by providing for oneself (hereinafter referred to as TQW), adult's clinical dosage is 0.045g/kg, and rat dose,equivalent and people are scaled 7 times of people's clinical dosages.Face the used time capsule 's content (brown powder) taking-up pure water is prepared.During test, rat TQW low dose group is 0.63g/kg (two times of clinical dosage), and high dose group is 1.26g/kg (four times of clinical dosage).
1.1.2.2 streptozotocin (Streptozotocin STZ), Beijing is won Alto and is reached Science and Technology Ltd., lot number: 040M1367.
1.1.2.3 rat insulin test kit: Manufactured by Mercodia AB, Sylveniusgatan8A, SE-75450Uppsala, Sweden.Lot number: 20518, used time by specification operation.
1.1.2.4 rat C peptide reagent box: upper sea blue base Science and Technology Ltd., lot number: 20130617, used time by specification operation.
1.1.2.5 metformin: be Tian An board Dimethyldiguanide hydrochloride enteric solubility tablet (lot number 20121144), adult's clinical dosage is 0.03g/kg every day, is scaled rat equivalent 0.21g/kg.
1.1.2.6 normal diet is purchased from Chongqing and rises prosperous Bill's laboratory animal sale company limited.
1.1.2.7 high-sugar-fat-diet makes: white sugar, Adeps Sus domestica, egg are all purchased from supermarket, and egg boils only with egg yolk, and normal diet is broken into powder.Feed formula: containing normal diet 35g (Chongqing Teng Xin Bill laboratory animal sells company limited) in every 100g high lipid food, Adeps Sus domestica 15g, white sugar 25g, egg yolk 25g, feeding animals 20 days.
1.2 animal grouping and medications
1.2.1 give TQW in advance to test the impact of type 2 diabetes mellitus rat: rat is divided into 3 groups, be respectively normal group, model group, TQW group.Normal group gives normal diet, model group and TQW group high-sugar-fat-diet are fed, TQW group gavage every day gives TQW (0.63g/kg, 1 times/day), after 20 days simultaneously, model group and TQW group lumbar injection STZ (face the used time to prepare with citrate buffer, pH value 4.2,30mg/kg, completed injection in 30 minutes), manufacture diabetes model, filter out modeling successful rat normal diet and feed 12 days (the omnidistance administration of TQW group 32 days).
1.2.2TQW the impact of type 2 diabetes mellitus rat is tested: rat is divided into 5 groups, normal group, model group, metformin group, TQW low dose group, TQW high dose group.Normal group gives normal diet, and other 4 groups of high-sugar-fat-diets feed modeling (the same) after 20 days, and the successful rat of modeling is used normal diet instead and feeds, and each group starts administration, 2 times/d, each 1 time of upper and lower noon simultaneously.Metformin group ig0.21g/kg, TQW low dosage ig0.63g/kg, (two times of clinical dosages), TQW high dose ig1.26g/kg (four times of clinical dosages).Omnidistance administration 27 days.
1.2.3TQW test with the impact of Western medicine conbined usage on type 2 diabetes mellitus rat and normal rat: rat is divided into 4 groups, normal group, model group, metformin+TQW low dose group, normal+TQW high dose group.Normal group and normal+TQW high dose group give normal diet, model group, metformin+TQW low dose group high lipid food feed modeling (the same) after 20 days, and the successful rat of screening modeling is used normal diet instead and feeds, and each group starts administration simultaneously, 2 times/d, each 1 time of upper and lower noon.Metformin+TQW low dose group first gives metformin 27 days (ig, 0.21g/kg), then changes TQW low dosage (ig, 0.63g/kg, two times of clinical dosages) 21 days into.Normally+TQW high dose group was to TQW high dose (ig, 1.26g/kg, four times of clinical dosages) 21 days.
1.3 detection methods and instrument
1.3.1 insulin, C peptide all detect by ELISA method, detecting instrument Biotek Synergy2 fluorescence microplate reader, U.S. Biotek Products.
1.3.2 blood-sugar detecting instrument and reagent paper: U.S.'s Roche Products, ACCU-CHEK Pertorma.
1.4 check pathological section rat limosis are after 16 hours, and sacrificed by decapitation, gets pancreas and be placed in the fixing preservation of neutral formalin liquid, do pathology detection.This detection completes in Pathology Deparment of No. 2 Affiliated Hospital of Guiyang College of Traditional Chinese Medicine.Be divided into normal and atrophy according to the atrophy degree after pancreas is damaged, carry out statistics (card side) and check by often organizing atrophy and normal number of elements and process.
1.5 statistical method: use SPSS17.0 statistical software, measurement data with
express, enumeration data is with percentage expression, and after group, measurement data compares with T inspection, and enumeration data compares with X 2 test.
2. result
2.1 give the impact of TQW on type 2 diabetes mellitus rat in advance
2.1.1 carbohydrate tolerance: rat limosis is after 16 hours, gives glucose solution (gavage, 20g/100mL, 3mL/ are only), measures empty stomach, 1h, 2h, 3h blood glucose value of rat, the results are shown in Table 9, Fig. 1:
Table 9 is in advance to the impact of TQW on type 2 diabetes mellitus rat carbohydrate tolerance
Note: compare with normal group, * p < 0.05, * * p < 0.01; Compare with model group, #p < 0.05, ##p < 0.01.
Be starkly lower than model group (P < 0.05) from the blood glucose value of table 9, Fig. 1: TQW group 3h, other two time points also have reduction; Illustrate that dye yam extract has preventive effect to type 2 diabetes mellitus.
2.1.2 pancreatic tissue check pathological section
Pathology detection result point out, in advance to TQW group comparatively model group Pancreas pathology damage obviously alleviate.In table 10, Fig. 2-Fig. 4 (HE dyeing × 400):
Table 10 is in advance to the impact (unit: only) of TQW on type 2 diabetes mellitus pancreas in rat
Note: compare with normal group, * p < 0.05; Compare with model group, #p < 0.05.
2.2TQW is on the impact of type 2 diabetes mellitus rat
2.2.1 body weight
TQW significantly can improve the body weight that diabetes rat reduces, and the results are shown in Table 11, Fig. 5:
Table 11TQW is on the impact of type 2 diabetes mellitus rat body weight
Note: compare with normal group, * p < 0.05, * * p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01
2.2.2 carbohydrate tolerance
Rat limosis, after 16 hours, gives glucose solution (gavage, 20g/100mL, 3mL/ are only), uses Roche blood glucose meter to measure empty stomach, 1h, 2h, 3h blood glucose value.The results are shown in Table 12, Fig. 6:
Table 12TQW is on the impact of type 2 diabetes mellitus rat carbohydrate tolerance
Note: compare with normal group, * p < 0.05, * * p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01.
From table 12, Fig. 6, the fasting glucose of each group of rat does not have significant difference, the blood glucose value of TQW low dosage and each time point of high dose all lower than model group, difference significance (p < 0.01), but still variant with normal group.There was no significant difference between Chinese medicine TQW low dose group and Chinese medicine TQW high dose group, compared with metformin group, the two has obvious blood sugar reducing function equally.
2.2.3 insulin and C peptide
Rat limosis, after 16 hours, gets blood centrifuging and taking supernatant, uses rat insulin ELISA kit (Mercodia), rat C peptide ELISA kit (BluGene), detects the OD value at 450nm wavelength place, the results are shown in Table 13:
Table 13TQW is on the impact of type 2 diabetes mellitus rat limosis insulin, C peptide
Note: compare with normal group, * p < 0.05, * * p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01
As shown in Table 13, the insulin of model group is significantly lower than normal group, and TQW high and low dose group insulin comparatively model group has increase trend, but still is starkly lower than normal group, and TQW high and low dose group is obviously better than metformin group.C peptide result shows, and model group decreases, and TQW high and low dose group comparatively model group has and slightly increases trend, and TQW high and low dose group is better than metformin group.
2.2.4 Pancreas pathology inspection
Gather pancreas and be placed in the fixing preservation of neutral formalin liquid, check pathological section, the results are shown in Table 14, Fig. 7-Figure 11 (HE dyeing × 400):
Table 14TQW is on the impact (unit: only) of type 2 diabetes mellitus pancreas
Note: compare with normal group, * p < 0.05; Compare with model group,
#p < 0.05
Table 14 illustrates that TQW high and low dose group and metformin group have certain protective role to rat Langerhans islet, and the protective effect of TQW high and low dose group is better than metformin group.
2.3TQW and metformin conbined usage are on the impact of type 2 diabetes mellitus rat
2.3.1 carbohydrate tolerance:
Rat limosis, after 16 hours, gives glucose solution (gavage, 20g/100mL, 3mL/ are only), measures empty stomach, 1h, 2h, 3h blood glucose value of rat.The results are shown in Table 15, Figure 12:
Table 15 drug combination is on the impact of type 2 diabetes mellitus rat carbohydrate tolerance
Note: compare with normal group, * p < 0.05, * * p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01
From table 15, Figure 12, metformin+TQW low dose group fasting glucose is significantly lower than model group, and normal+TQW high dose group and normal group carbohydrate tolerance value do not have difference, illustrate that this TQW does not affect blood glucose level normal.
2.3.2 Pancreas pathology inspection
Gather pancreas and be placed in that neutral formalin liquid is fixing to be preserved, do pathology detection, the results are shown in Table 16, Figure 13-Figure 16 (HE dyeing × 400):
Table 16 drug combination is on the impact (unit: only) of pancreas in rat check pathological section
Note: compare with normal group, * p < 0.05
As shown in Table 16: this first 3 groups of test compares, and result metformin+TQW low dose group has certain protective role to rat Langerhans islet, but does not have statistical significance.Normally+TQW high dose group compares with normal group, does not have diversity between two groups, illustrates that the TQW of high dose does not affect normal pancreas in rat.
Conclusion:
This experiment male SD rat, feeds with high calorie and adds the classical way of half amount streptozotocin partial destruction B cell, successfully construct type 2 diabetes mellitus rat model.
This research finds, it is no matter the method with the method for administration in advance or conventional therapy administration, no matter be individually dosed method or the method with metformin administering drug combinations, no matter take carbohydrate tolerance as index observing or be index observing with conventional blood sugar, TQW all obviously can reduce type 2 diabetes mellitus rat blood sugar (the equal < 0.05 of P value), shows the obvious blood sugar reducing function of TQW tool.
This research also finds, after TQW acts on type 2 diabetes mellitus rat, while blood glucose obviously reduces, its fasting insulin and C peptide there is no obvious change, show this blood sugar reducing function mechanism not necessarily B cell be short to secrete effect, may be relevant with improving the factors such as insulin resistant (IR).Also should observe Postprandial insulin and C peptide further, and observe insulin sensitivity further.
This research observes the change of the Neo-Confucianism of the Pancreas Disease after TQW effect; find that its atrophy number is starkly lower than the model group (P < 0.05) without TQW effect, show that TQW has islets of langerhans protective effect to a certain degree to type 2 diabetes mellitus rat.
TQW is acted on normal SD rats by this research, and it found that the blood glucose of normal SD rats is unchanged before and after TQW effect, and its pancreas, also without pathological change, shows TQW to normal rat without blood sugar influence, also has no significant effect its islets of langerhans.This result also shows that the blood sugar reducing function of TQW may not mainly through promoting that B cell excreting insulin realizes further.
Compared with prior art, the present invention adopts modern drug efficacy study technology to carry out deep development to Rhizoma Dioscoreae Cirrhosae, be that raw material can be processed into suitable pharmaceutical preparation for prevention or treatment diabetes and complication thereof with Rhizoma Dioscoreae Cirrhosae, its pharmacologically active is obvious, stable performance, safe and reliable.In addition, the raw material sources of Rhizoma Dioscoreae Cirrhosae are easy to get, and preparation technology is easy to industrialization, can drive the abundant development and utilization of herb resource.
Accompanying drawing explanation
Fig. 1 is in advance to the influence curve figure of TQW to the carbohydrate tolerance of type 2 diabetes mellitus rat;
Fig. 2 is that normal rats Pancreas pathology changes schematic diagram;
Fig. 3 is that model group rats Pancreas pathology changes schematic diagram;
Fig. 4 be in advance to TQW to type 2 diabetes mellitus pancreas in rat pathological change schematic diagram;
Fig. 5 is the influence curve figure of TQW to type 2 diabetes mellitus rat body weight;
Fig. 6 is the influence curve figure of TQW to the carbohydrate tolerance of type 2 diabetes mellitus rat;
Fig. 7 is the section schematic diagram of normal rats pancreas;
Fig. 8 is the section schematic diagram of model group rats pancreas;
Fig. 9 is the section schematic diagram of metformin group pancreas in rat;
Figure 10 is the section schematic diagram of TQW low dose group pancreas in rat;
Figure 11 is the section schematic diagram of TQW high dose group pancreas in rat;
Figure 12 is the influence curve figure of drug combination to the carbohydrate tolerance of type 2 diabetes mellitus rat;
Figure 13 is the pancreas schematic diagram of normal rats;
Figure 14 is the pancreas schematic diagram of model group rats;
Figure 15 is the pancreas schematic diagram that metformin adds TQW low dose group rat;
Figure 16 is the pancreas schematic diagram normally adding TQW high dose group rat.
Below in conjunction with the drawings and specific embodiments, the present invention is further illustrated.
Detailed description of the invention
Embodiments of the invention 1: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, infiltrate 30min with 8 times of water gagings by medical material, decoct 2 times, each 2 hours, filter, merging filtrate, concentrated, in temperature be 70 DEG C, vacuum be the condition of 0.1Mpa under drying under reduced pressure, to obtain final product.
Embodiment 2: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 0.5cm section, take 90g, infiltrates 60min with 7 times of water gagings by medical material, decocts 2 times, each 2.5 hours, filter, merging filtrate, concentrated, in temperature be 68 DEG C, vacuum be the condition of 0.09Mpa under drying under reduced pressure, to obtain final product.
Embodiment 3: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 2cm section, take 120g, infiltrates 120min with 10 times of water gagings by medical material, decocts 3 times, each 3 hours, filter, merging filtrate, concentrated, in temperature be 75 DEG C, vacuum be the condition of 0.1Mpa under drying under reduced pressure, to obtain final product.
Embodiment 4: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 0.02cm section, take 80g, infiltrates 30min with 6 times of water gagings by medical material, decocts 1 hour, filters, concentrated, in temperature be 65 DEG C, vacuum be the condition of 0.08Mpa under drying under reduced pressure, to obtain final product.
Embodiment 5: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, adds 5% alcohol reflux 2 times of 10 times of medical material amounts, each 2 hours, filter, merging filtrate, concentrated, in temperature be 72 DEG C, vacuum be the condition of 0.09Mpa under drying under reduced pressure, to obtain final product.
Embodiment 6: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, adds 40% alcohol reflux 2 times of 10 times of medical material amounts, each 2 hours, filter, merging filtrate, concentrated, in temperature be 72 DEG C, vacuum be the condition of 0.09Mpa under drying under reduced pressure, to obtain final product.
Embodiment 7: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, adds 80% alcohol reflux 2 times of 10 times of medical material amounts, each 2 hours, filter, merging filtrate, concentrated, in temperature be 72 DEG C, vacuum be the condition of 0.09Mpa under drying under reduced pressure, to obtain final product.
Embodiment 8: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, adds 95% alcohol reflux 2 times of 10 times of medical material amounts, each 2 hours, filter, merging filtrate, concentrated, in temperature be 72 DEG C, vacuum be the condition of 0.09Mpa under drying under reduced pressure, to obtain final product.
Embodiment 9: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, CO2 supercritical extraction, wherein, make entrainer with the ethanol that mass ratio is 5%, extracting pressure is 30Mpa, and extraction temperature is 50 DEG C, and the static immersing time is 3h, dynamic extraction 3h, drying under reduced pressure, to obtain final product.
Embodiment 10: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, CO2 supercritical extraction, wherein, make entrainer with the ethanol that mass ratio is 40%, extracting pressure is 30Mpa, and extraction temperature is 50 DEG C, and the static immersing time is 3h, dynamic extraction 3h, drying under reduced pressure, to obtain final product.
Embodiment 11: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, CO2 supercritical extraction, wherein, make entrainer with the ethanol that mass ratio is 75%, extracting pressure is 30Mpa, and extraction temperature is 50 DEG C, and the static immersing time is 3h, dynamic extraction 3h, drying under reduced pressure, to obtain final product.
Embodiment 12: the preparation of dye yam extract: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, CO2 supercritical extraction, wherein, make entrainer with the ethanol that mass ratio is 95%, extracting pressure is 30Mpa, and extraction temperature is 50 DEG C, and the static immersing time is 3h, dynamic extraction 3h, drying under reduced pressure, to obtain final product.
Embodiment 13: the dye yam extract of the arbitrary gained of Example 1 ~ 4, adds appropriate customary adjuvant, mixing, dries, sterilizing, loads hard capsule, and packaging, makes capsule.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, can be used for treatment type 2 diabetes mellitus and complication thereof.
Embodiment 14: the dye yam extract of the arbitrary gained of Example 5 ~ 8, adds appropriate solubilizing agent, grinding, add the dilution of a small amount of water, mixing, adds correctives and antiseptic, and mixing, adds water to ormal weight, filters, and mixing, subpackage, sterilizing, makes oral liquid.Said preparation day takes 1 ~ 3 time, each 10 ~ 20ml, for the treatment of type 2 diabetes mellitus and complication thereof.
Embodiment 15: the dye yam extract of the arbitrary gained of Example 9 ~ 12, add appropriate customary adjuvant, mixing, makes granule, and dry, tabletting, makes tablet.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, for the control of diabetes and complication thereof.
Embodiment 16: the dye yam extract of the arbitrary gained of Example 1 ~ 4, adds appropriate conventional adjuvant, becomes ball, dry, makes pill.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 17: the dye yam extract of the arbitrary gained of Example 1 ~ 12, separately gets Lonicera confusa extract, adds appropriate customary adjuvant, and mixing, makes granule.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 18: the dye yam extract of the arbitrary gained of Example 5 ~ 8, separately gets fresh Caulis Spatholobi extract, adds appropriate customary adjuvant, and mixing, makes soft capsule.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 19: the dye yam extract of the arbitrary gained of Example 9 ~ 12, separately gets Herba Agrimoniae extract, adds appropriate customary adjuvant, and mixing, makes drop pill.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 20: the dye yam extract of the arbitrary gained of Example 1 ~ 8, separately get fresh vertical basin squeeze the juice mix slag zymolysis become song, add appropriate customary adjuvant, mixing, make powder.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 21: the dye yam extract of the arbitrary gained of Example 9 ~ 12, separately gets fresh Fructus Trichosanthis (containing Pericarpium Trichosanthis, Semen Trichosanthis and Radix Trichosanthis), adds appropriate customary adjuvant, and mixing, makes dispersible tablet.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Embodiment 22: the dye yam extract of the arbitrary gained of Example 5 ~ 12, separately get Flos Lonicerae, freshly-slaughtered poultry Caulis seu Radix Schisandrae Henryi, Herba Agrimoniae, fresh vertical basin squeeze the juice mix in song that slag zymolysis becomes, fresh Fructus Trichosanthis (containing Pericarpium Trichosanthis, Semen Trichosanthis and Radix Trichosanthis) one or more, add appropriate customary adjuvant, mixing, makes microcapsule.Said preparation day takes 1 ~ 3 time, each 10 ~ 20mg, is used for the treatment of diabetes and complication thereof.
Claims (10)
1. Rhizoma Dioscoreae Cirrhosae prevents in preparation or treats the application in the medicine of diabetes and complication thereof.
2. the application of Rhizoma Dioscoreae Cirrhosae according to claim 1, is characterized in that, described diabetes are type 2 diabetes mellitus; Described complication be vision change, auditory dysesthesia, gingival hemorrhage, xerostomia or ulcer, dizziness or feel dizzy, extremity twinge or numbness, the frequent pain of trick, leg cramps or numbness, intestinal and bladder dysfunction, perspiration are abnormal, xerosis cutis or pruritus, sexual life difficulty, dyslipidemia.
3. the application of Rhizoma Dioscoreae Cirrhosae according to claim 1, is characterized in that, Rhizoma Dioscoreae Cirrhosae is used for prevention or treatment type 2 diabetes mellitus, is be raw material with Rhizoma Dioscoreae Cirrhosae, is prepared into the medicine or health product that are applicable to use clinically.
4. the application of Rhizoma Dioscoreae Cirrhosae according to claim 3, it is characterized in that, described medicine or health product are powder, tablet, granule, capsule, microcapsule, pill, drop pill, soft capsule, oral liquid, syrup, dispersible tablet, spray or aerosol, intravenous injection, intramuscular dose, inhalant, patch, gel; Adjuvant used is selected from conventional solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent, lubricant, wetting agent, thickening agent, solubilizing agent.
5. the application of the Rhizoma Dioscoreae Cirrhosae according to claim 3 or 4, is characterized in that, Rhizoma Dioscoreae Cirrhosae is used for prevention or treatment type 2 diabetes mellitus, is the dye yam extract extracted for solvent with water, ethanol or carbon dioxide, is prepared into the medicine or health product that are applicable to use clinically.
6. the application of Rhizoma Dioscoreae Cirrhosae according to claim 5, it is characterized in that, be that solvent extraction dye yam extract comprises the following steps with water: Rhizoma Dioscoreae Cirrhosae is cut into 0.02 ~ 2cm section, take 80 ~ 120g, with 6 ~ 10 times of water gagings, medical material is infiltrated 30 ~ 120min, decoct 1 ~ 3 time, each 1 ~ 3 hour, filter, merging filtrate, concentrated, in temperature be 65 ~ 75 DEG C, vacuum be the condition of 0.08 ~ 0.1Mpa under drying under reduced pressure, to obtain final product.
7. the application of Rhizoma Dioscoreae Cirrhosae according to claim 6, it is characterized in that, be that solvent extraction dye yam extract comprises the following steps with water: Rhizoma Dioscoreae Cirrhosae is cut into 1cm section, take 100g, with 8 times of water gagings, medical material is infiltrated 30min, decoct 2 times, each 2 hours, filter, merging filtrate, concentrated, in temperature be 65 ~ 75 DEG C, vacuum be the condition of 0.08 ~ 0.1Mpa under drying under reduced pressure, to obtain final product.
8., according to the application of the arbitrary described Rhizoma Dioscoreae Cirrhosae of claim 5 ~ 7, it is characterized in that, dye yam extract and other drug regimen for the treatment of diabetes are made compound medicine.
9. the application of Rhizoma Dioscoreae Cirrhosae according to claim 8, is characterized in that, by the heat and toxic materials clearing away medicine of dye yam extract with treatment diabetes deficiency of both QI and YIN, circulation promoting vein relaxing medicine, astringent hemostatic, Qi-tonifying drug, the one or more combination in clearing away heat-fire, relieving stuffiness of the chest by dispersing aggregation of pathogens, promoting the production of body fluid to quench thirst medicine makes compound medicine.
10. the application of Rhizoma Dioscoreae Cirrhosae according to claim 9, it is characterized in that, described heat and toxic materials clearing away medicine is Flos Lonicerae, circulation promoting vein relaxing medicine is freshly-slaughtered poultry Caulis seu Radix Schisandrae Henryi, astringent hemostatic is Herba Agrimoniae, Qi-tonifying drug be fresh Herba Sedi squeeze the juice mix slag zymolysis become song, clearing away heat-fire, relieving stuffiness of the chest by dispersing aggregation of pathogens, promoting the production of body fluid to quench thirst medicine are fresh Fructus Trichosanthis (containing Pericarpium Trichosanthis, Semen Trichosanthis, Radix Trichosanthis).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410135470.9A CN104971190A (en) | 2014-04-04 | 2014-04-04 | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410135470.9A CN104971190A (en) | 2014-04-04 | 2014-04-04 | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104971190A true CN104971190A (en) | 2015-10-14 |
Family
ID=54268511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410135470.9A Pending CN104971190A (en) | 2014-04-04 | 2014-04-04 | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104971190A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924323A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix macrotomiae in the medicine for preparing treatment virus B hepatitis |
| CN106924321A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the Artemisia japonica in the medicine for preparing treatment virus B hepatitis |
| CN106924313A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the witloof in the medicine for preparing treatment virus B hepatitis |
| CN106924307A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis |
| CN109568468A (en) * | 2018-12-10 | 2019-04-05 | 江西赣隆药业有限公司 | A kind of dye yam granule and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736457A (en) * | 2005-06-16 | 2006-02-22 | 中国人民解放军海军医学研究所 | Application of dye yam extract in preparation of anti-tumor medicine |
-
2014
- 2014-04-04 CN CN201410135470.9A patent/CN104971190A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736457A (en) * | 2005-06-16 | 2006-02-22 | 中国人民解放军海军医学研究所 | Application of dye yam extract in preparation of anti-tumor medicine |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924323A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix macrotomiae in the medicine for preparing treatment virus B hepatitis |
| CN106924321A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the Artemisia japonica in the medicine for preparing treatment virus B hepatitis |
| CN106924313A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the witloof in the medicine for preparing treatment virus B hepatitis |
| CN106924307A (en) * | 2015-12-30 | 2017-07-07 | 姚萍 | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis |
| CN109568468A (en) * | 2018-12-10 | 2019-04-05 | 江西赣隆药业有限公司 | A kind of dye yam granule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104971190A (en) | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes | |
| CN105031591B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN104337871A (en) | Blood sugar reducing capsule | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN106176773A (en) | Berberine hydrochloride and stachyose composition compositions and application | |
| CN104840777A (en) | Diabetes treating traditional Chinese medicine preparation and preparation method thereof | |
| CN101647951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
| CN105664097A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN102631526A (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN103690582A (en) | Composition containing dendrobium polysaccharide and atractylodes oil and application thereof | |
| CN102784237A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| KR101660232B1 (en) | Hypoglycemic agent with a natural plant and manufacturing method | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN104689079A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| US9433657B2 (en) | Healthcare food with anti-diabetic effect and preparation method thereof | |
| RU2805492C9 (en) | Method for correction of post-prandial glycemia | |
| CN105582041A (en) | Application of hemsleya amabilis diels in preparing medicine for preventing or treating diabetics and complications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518000 Guangdong, Shenzhen, Futian District Meishan Road, 16, 5, 902 Applicant after: Zhang Min Address before: 518035 6-303 East Hua Fu Village, 2001 Hua Fu Road, Futian District, Shenzhen, Guangdong Applicant before: Zhang Min |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151014 |